Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles William Heard’s Decision to Shutter His Long-Short Fund Pays Off Stephen Taub Old-School Playbook Finds New Life in Middle-Market Private Equity John Crabb Paying it Forward: A Fidelity CIO’s Journey to Purposeful Philanthropy Sponsored by Fidelity Investments